Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use

Details Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use

2011-03-22

2011-03-22

Jiang, Dong (Department: 1646)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S388100, C530S809000, C530S351000, C435S070210, C435S069700

Reexamination Certificate

active

07910703

ABSTRACT:
The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

REFERENCES:
patent: 6274711 (2001-08-01), Golstein et al.
patent: 6495667 (2002-12-01), Bazan
patent: 7282204 (2007-10-01), Oft et al.
patent: 7422743 (2008-09-01), Chirica et al.
patent: 7427402 (2008-09-01), Kastelein et al.
patent: 7485297 (2009-02-01), Wood et al.
patent: 7491391 (2009-02-01), Benson et al.
patent: 7608690 (2009-10-01), Bazan
patent: 2004/0219150 (2004-02-01), Cua et al.
patent: 2005/0158750 (2005-07-01), Bazan
patent: 2005/0208052 (2005-09-01), Katsikis et al.
patent: 2005/0244874 (2005-11-01), Kastelein et al.
patent: 2006/0134112 (2006-06-01), Cua et al.
patent: 2007/0009526 (2007-01-01), Benson et al.
patent: 2007/0648315 (2007-03-01), Presta
patent: 2007/0098727 (2007-05-01), Kastelein et al.
patent: 2007/0166795 (2007-07-01), Hirata
patent: 2007/0212362 (2007-09-01), Filvaroff
patent: 2007/0218065 (2007-09-01), Jaspers et al.
patent: 2007/0269428 (2007-11-01), Christie et al.
patent: 2008/0095775 (2008-04-01), Lewis et al.
patent: 2008/0269467 (2008-10-01), Allan et al.
patent: 2008/0317748 (2008-12-01), Chirica et al.
patent: 2009/0004199 (2009-01-01), Jaspers et al.
patent: 2010/0041144 (2010-02-01), Bazan
patent: 99/05280 (1999-02-01), None
patent: 99/54357 (1999-10-01), None
patent: 01/18051 (2001-03-01), None
patent: 2004/042009 (2004-05-01), None
patent: 2004/058178 (2004-07-01), None
patent: 2004/071517 (2004-08-01), None
patent: 2004/081190 (2004-09-01), None
patent: 2004/106377 (2004-12-01), None
patent: 2005/010044 (2005-02-01), None
patent: 2005/051422 (2005-06-01), None
patent: 2006/013107 (2006-02-01), None
patent: 2006/020706 (2006-02-01), None
patent: 2006/054059 (2006-05-01), None
patent: 2007/005955 (2007-01-01), None
patent: 2007/024846 (2007-03-01), None
patent: 2007/027114 (2007-03-01), None
patent: 2007/027761 (2007-03-01), None
patent: 2007/051169 (2007-05-01), None
patent: 2007/070750 (2007-06-01), None
patent: 2007/076523 (2007-07-01), None
patent: 2007/076524 (2007-07-01), None
patent: 2007/106769 (2007-09-01), None
patent: 2007/147019 (2007-12-01), None
patent: 2007/149032 (2007-12-01), None
patent: 2008/001063 (2008-01-01), None
patent: 2008/021156 (2008-02-01), None
patent: 2008/047134 (2008-04-01), None
patent: 2008/103432 (2008-08-01), None
patent: 2008/103473 (2008-08-01), None
patent: 2008/106131 (2008-09-01), None
patent: 2008/133684 (2008-11-01), None
patent: 2009/082624 (2009-07-01), None
Iwakura et al. The IL-23/IL-17 axis in inflammation. J Clin Invest. May 2006;116(5):1218-22.
Sequence alignment between SEQ ID No. 2 and SEQ ID No. 6. Accessed Jul. 16, 2009.
McKenzie et al., “Understanding the IL-23—IL-17 immune pathway,” Trends in Immunology, 27(1): Jan. 17-23, 2006, Elsevier, Rahway, NJ.
Bowman et al., “Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy,” Current Opinion in Infectious Diseases, 19(3): 245-252, Jun. 2006.
Chen et al., “Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis,” Journal of Clinical Investigation, 116(5): 1317-1326, May 2006.
Wright et al., “Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells,” J Biol Chem 282(18):13447-13455, May 4, 2007. Epub Mar. 13, 2007.
Zhang et al., “After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease,” International Immunopharmacology 7(4): 409-416, Feb. 21, 2007. Elsevier, Amsterdam, NL.
Chan et al., “IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis,” Journal of Experimental Medicine 203(12): 2577-2587, Nov. 27, 2006. Rockefeller University Press, JP.
Jaspers and Presnell, U.S. Appl. No. 12/617,078, filed Nov. 12, 2009.
Mabry et al., “Engineering of stable bispecific antibodies targeting IL-17A and IL-23,” Protein Eng Des Sel, 23(3): 115-127, Mar. 2010.
Kuestner et al., “Humane and mouse IL-17A and IL-17F differentially bind IL-17RA and IL-17RC,” Keystone Cymposia - Cytokines, Disease and Therapeutic Intervention: 49, 2005.
Kuestner et al., “Identification of the IL-17 Receptor Related Molecule IL-17RC as the Receptor for IL-17F,” J Immunol. 179(8): 5462-73, Oct. 15, 2007.
Lewis et al., “Soluble Interleukin-17RA-Fc Reduces Disease Severity and Inflammatory Cytokines in Murine Oxazalone Colitis,” Cytokine 39(1): Jul. 24, 2007. (abstract).

Affiliated with

Also associated with

Rating

Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2700163